meayamycin: inhibits pre-mRNA splicing; has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 16111971 |
| CHEMBL ID | 3221255 |
| SCHEMBL ID | 12738836 |
| MeSH ID | M0542780 |
| Synonym |
|---|
| [(z,2s)-4-[[(2r,3r,5s,6s)-6-[(2e,4e)-5-[(3r,4r,5r)-4-hydroxy-7,7-dimethyl-1,6-dioxaspiro[2.5]octan-5-yl]-3-methyl-penta-2,4-dienyl]-2,5-dimethyl-oxan-3-yl]carbamoyl]but-3-en-2-yl] acetate |
| CHEMBL3221255 |
| SCHEMBL12738836 |
| meayamycin |
| [(z,2s)-5-[[(2r,3r,5s,6s)-6-[(2e,4e)-5-[(3r,4r,5r)-4-hydroxy-7,7-dimethyl-1,6-dioxaspiro[2.5]octan-5-yl]-3-methylpenta-2,4-dienyl]-2,5-dimethyloxan-3-yl]amino]-5-oxopent-3-en-2-yl] acetate |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1895052 | Cytotoxicity against human HCT116/VM46 cells assessed as inhibition in cell growth | 2021 | Journal of natural products, 05-28, Volume: 84, Issue:5 | Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors. |
| AID1895051 | Cytotoxicity against human HCT-116 cells assessed as inhibition in cell growth | 2021 | Journal of natural products, 05-28, Volume: 84, Issue:5 | Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors. |
| AID1895046 | Cytotoxicity against human MCF7 cells incubated for 7 to 10 days by MTS assay | 2021 | Journal of natural products, 05-28, Volume: 84, Issue:5 | Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors. |
| AID1895050 | Cytotoxicity against mouse L1210 cells assessed as inhibition in cell growth | 2021 | Journal of natural products, 05-28, Volume: 84, Issue:5 | Spliceostatins and Derivatives: Chemical Syntheses and Biological Properties of Potent Splicing Inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.03) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||